Adaptive Immunity: Effector and Inhibitory Cytokine Pathways in Gut Inflammation

Inflammatory Bowel Disease: Translating basic science into clinical practice

Volumn , Issue , 2010, Pages 82-91

  Macdonald, Thomas T ^a   Monteleone, Giovanni ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Adaptive immunity effector and inhibitory cytokine pathways in gut inflammation; CD4+T cells accumulate in IBD tissue; Smad signaling in IBD; TGF master regulator of inflammation in gut in health and disease; Th17 cells link between TGF and IL 21

Indexed keywords

EID: 84870183380     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444318418.ch8     Document Type: Chapter

References (51)

1. Strum A, Leite AZ, Danese S, et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 2004; 53:1624-31.
2. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999; 163:1081-90.
3. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:evidence in Crohn's disease and experimental colitis in vivo. Nat Med 2000; 6:583-8.
4. Van den Brande JM, Braat H, Van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in Iamina propria Tlymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-85.
5. DI Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53:70-7.
6. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359:693-9.
7. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12:171-1.
8. Nakamura K, Kitani A, Strober W, et al. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194:629-44.
9. Fuss IJ, Boirivant M, Lacy B, et al. The interrelated roles of TGFbeta and IL-10 in the regulation of experimental colitis. J Immunol 2002; 168:900-8.
10. Oida T, Zhang X, Goto M, et al. CD4+CD25-T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol 2003; 170:2516-22.
11. Piek E, Heldin CH, Ten Dijke P, et al. Specificity, diversity and regulation in TGF-beta superfamily signaling. FASEB J 1999; 13:2105-24.
12. Heldin CH, Miyazono K, Ten Dijke P, et al. TGF-beta signaling fromcellmembrance to nucleus throughSMADproteins. Nature 1997; 390:465-71.
13. Derynck R, Zhang Y, Feng XH, et al. Smads: transcriptional activators of TGF-beta responses. Cell 1998; 95-96:737-40.
14. Abdollah S,Macias-SilvaM, Tsukazaki T, et al. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 1997; 272:27678-85.
15. Dennler S, Itoh S, Viven D, et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17:3091-100.
16. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999; 18:1280-91.
17. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 1997; 89:1165-73.
18. Nakao A, Afrakhte M, Moŕen A, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signaling. Nature 1997; 389:631-5.
19. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108:601-9.
20. Monteleone G, Del Vecchio Blanco G, Palmieri G, et al. Induction and regulation of Smad7 in the gastric mucosaof patients with Helicobacter pylori infection. Gastroenterology 2004; 126:674-82.
21. Monteleone G, Mann J, Monteleone I, et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem 2004; 279:3925-32.
22. Ulloa L, Doody J, Massagúe J, et al. Inhibition of transforming growth factor-beta/SMAD signaling by the interferongamma/ STAT pathway. Nature 1999; 397:710-13.
23. Monteleone G, Del Vecchio Blanco G, Monteleone I, et al. Posttranscriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology 2005; 129:1420-29.
24. Gr̈onroos E, Hellman U, Heldin CH, et al. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 2002; 10:483-93.
25. Itoh S, ten Dijke P, et al. Negative regulation of TGF-beta receptor/ Smad signal transduction. Curr Opin Cell Biol 2007; 19: 176-84.
26. Hong S, Lim S, Allen G, et al. Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. Nat Immunol 2007; 8:504-13.
27. Cebrat M. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase. Bioorg Med Chem 2003; 11:3307-13.
28. Rahman I, Marwick J, Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-B and pro-inflammatory gene expression. Biochem Pharmacol 2004; 68:1255-67.
29. Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel P300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histoneacetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279:51163-71.
30. Sugimoto S, et al. Curcumin prevents and ameliorates TNBS colitis in mice. Gastroenterology 2002; 123:1912-22.
31. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005; 50:2191-3.
32. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintainance therapy for ulcerative colitis: randomized, multicenter, doubleblind, placebo-controlled trial. Clin GastroenterolHepatol 2006; 12: 1502-6.
33. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGFbeta1- mediated suppression of colitis. Gastroenterology 2006; 131: 1786-98.
34. Monteleone G, Monteleone I, FinaDet al. Interlukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005; 128:687-94.
35. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte. Nature 2000; 408:57-63. Adaptive Immunity 91
36. Strengell M, Sareneva T, Foster D, et al. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 2002; 169:3600-5.
37. Kasaian MT, Whitters MJ, Carter LL, et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002; 16:559-69.
38. Wang G, Tschoi M, Spolski R, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003; 63:9016-22.
39. Pene J, Gauchat JF, Lecart S, et al. Cutting edge: IL-21 is switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol 2004; 172:5154-7.
40. Caruso R, Fina D, Peluso I, et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant,MIP- 3alpha by gut epithelial cells. Gastroenterology 2007; 132:166-75.
41. MacDonald TT, et al. Mechanisms of tissue injury. In: Kirsner's Inflammatory BowelDisease (ed. RB Sartor,WSandborn), London: Saunders, 2004, pp.163-78.
42. Monteleone G, Caruso R, Fina D, et al. Control ofmatrixmetalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006; 55:1774-80.
43. Pesce J, Kaviratne M, Ramalingam TR, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 2006; 116:2044-55.
44. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849-61.
45. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin-17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
46. Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006; 12:382-8.
47. Zhou L, Ivanov II, Spolski R, et al. IL-6 programmes Th-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8:967-74.
48. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448:484-7.
49. Mucida D, Park Y, KimGet al. Reciprocal T(H)17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317:256-60.
50. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-7.
51. Fantini MC, Rizzo A, Fina D, et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007; 37:3155-63.